DAC group comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
They are an important item in sadya, a vegetarian feast prepared during festive occasions in Kerala. The chips are typically labeled "plantain chips" when they are made of green plantains that taste starchy, like potato chips. In Tamil Nadu, a thin variety made from green plantains is used to make chips seasoned with salt, chili powder and asafoetida. In the western/central Indian language Marathi, the plantain is called rajeli kela (figuratively meaning "king-sized" banana), and is often used to make fried chips.
Gee highlighted particular success with a child fed "a quart of the best Dutch mussels daily"; the child could not bear this diet for more than one season. Christian Archibald Herter, an American physician, wrote a book in 1908 on children with coeliac disease, which he called "intestinal infantilism". He noted their growth was retarded and that fat was better tolerated than carbohydrate. The eponym Gee-Herter disease was sometimes used to acknowledge both contributions. Sidney V. Haas, an American paediatrician, reported positive effects of a diet of bananas in 1924. This diet remained in vogue until the actual cause of coeliac disease was determined. While a role for carbohydrates had been suspected, the link with wheat was not made until the 1940s by the Dutch paediatrician Willem Karel Dicke. Clinical improvement of his patients during the Dutch famine of 1944–1945 (during which flour was scarce) likely contributed to his discovery. Dicke noticed that the shortage of bread led to a significant drop in the death rate among children affected by coeliac disease from greater than 35% to essentially zero. He also reported that once wheat was again available after the conflict, the mortality rate soared to previous levels. The link with the gluten component of wheat was made in 1952 by a team from Birmingham, England. Villous atrophy was described by British physician John W. Paulley in 1954 on samples taken at surgery. This encouraged biopsy samples taken by endoscopy. Throughout the 1960s, other features of coeliac disease were elucidated.
In 2023, 88% of the Portuguese population lived in urban areas. The capital city, Lisbon, had a population of 658,236 as of 2025. It is part of Lisbon metropolitan area, the biggest metropolitan area of Portugal with 3.4 million people.
Number average molar mass (Mn), also loosely referred to as number average molecular weight (NAMW). Mass average molar mass (Mw), where w stands for weight; also commonly referred to as weight average or weight average molecular weight (WAMW). Z-average molar mass (Mz), where z stands for centrifugation (from German Zentrifuge). Viscosity average molar mass (Mv).
Sources: en.wikipedia.org
They can be synthesized/released and broken down again in specific reactions by enzymes or ion channels. Some (such as Ca2+) can be stored in special organelles and quickly released when needed. Their production/release and destruction can be localized, enabling the cell to limit space and time of signal activity.
Protein-fructosamine 3-kinase (EC 2.7.1.171, FN3K, fructosamine 3-kinase) is an enzyme with systematic name ATP:(protein)-N6-D-fructosyl-L-lysine 3-phosphotransferase. This enzyme catalyses the following chemical reaction
Acetaldehyde (ethereal) Hexanal (green, grassy) cis-3-Hexenal (green tomatoes) Furfural (burnt oats) Hexyl cinnamaldehyde Isovaleraldehyde – nutty, fruity, cocoa-like Anisic aldehyde – floral, sweet, hawthorn. It is a crucial component of chocolate, vanilla, strawberry, raspberry, apricot, and others. Cuminaldehyde – Spicy, cumin-like, green
== Maintenance == When maintaining the aquariums for this breed, instead of using substrate, breeders go for driftwood roots or branches, bark of Beech or oak and position them in a way that offers some kind of shades to the fish. To add to the natural environment, dry leaves are also used, which along with the Tannin from the wood, act as a supplement fish food when decomposed. For king bettas, always dim lighting and aquatic vegetation like Microsorum pteropus and Taxiphyllum barbieri is advised. A sprinkling of floating aquatic plants also help to maintain the lighting in the tank. An air-powered sponge filter in place of other forms of filtration gadgets are preferred. As these species tend to make jumps, the tank should be covered, but care should be taken not to fill it to the brim as the fish seek the humid air that develops in the empty space.
Chell can pick up weighted storage cubes and use them to climb or hold down large buttons that activate doors and other mechanisms. Particle fields known as "Emancipation Grills" appear at the ends of test chambers and in other locations; passing through them removes active portals and destroys objects carried through them. The fields also prevent the player from firing portals through them. Chell is equipped with mechanical heel springs that reduce the effects of falling, but she can still be killed by hazards including automated turrets, energy projectiles, toxic liquid, falling objects, and crushing mechanisms. The game does not display a conventional health bar; instead, Chell dies after sustaining sufficient damage within a short period. Certain hazards, including some energy projectiles and crushing mechanisms, can kill her immediately. The test chambers can be completed through different solutions, with players able to use the portal mechanics and physics in different ways to overcome the puzzles. After completing the main game, two additional modes become available: Challenge Chambers and Advanced Chambers. Challenge Chambers revisit existing test chambers with additional objectives based on completing them with the fewest portals, the fewest footsteps, or the shortest time. Advanced Chambers modify existing chambers by adding obstacles and other hazards.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.